Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from BioNTech

Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins

Key takeaways:

Benzinga · Mar 28, 2022

Overview Of Value Stocks In The Healthcare Sector

What are Value Stocks?

Benzinga · Mar 28, 2022

Fosun Reports $157 Million of China mRNA Vaccine Sales in 2021

BioNTech partner markets the advanced-tech inoculation in Hong Kong, Macao and Taiwan as regulators haven’t cleared the shots for the mainland

Caixin Global · Mar 23, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

No funds to buy fourth Covid vaccine dose for all Americans, White House warns

Funding for coronavirus aid stalled in Congress leaving vaccine and therapeutics purchases lacking

The Independent UK · Mar 22, 2022

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Financial Times · Mar 20, 2022

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Mar 16, 2022

Pfizer-BioNTech Seek US Approval of Second Covid Booster for 65+

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older. The companies said in a press statement that their request is based off two Israeli studies that show…

Asharq Al-Awsat · Mar 16, 2022

Read news from The Economist, FT, and more,
with one subscription

Pfizer and BioNTech plan to seek authorization for second COVID booster for people 65 and up

The move is an attempt to bolster waning immunity that occurs several months after a first booster shot.

Axios · Mar 15, 2022

Here's Why BioNTech Shares Are Rising On Monday

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 14.8% at $155.65. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.

Benzinga · Mar 14, 2022

How drug companies are sidestepping the WHO's technology transfer hub in Africa

Pharmaceutical company Moderna announced on 7 March 2022 that it would develop a site in Kenya to manufacture COVID-19 vaccines. The company holds much of the key intellectual property relating to the messenger RNA (mRNA) vaccines. Due to their higher efficacy, mRNA vaccines are the preferred option in developed countries.…

The Conversation · Mar 13, 2022

BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share…

Benzinga · Mar 8, 2022

Where BioNTech Stands With Analysts

BioNTech (NASDAQ:BNTX) has observed the following analyst ratings within the last quarter:

Benzinga · Feb 23, 2022

BioNTech, Medigene Ink Immunotherapy Pact Against Cancer

BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer.

Benzinga · Feb 22, 2022

Pfizer/BioNTech's Omicron-Targeted COVID-19 To Miss March Timeline: Reuters

Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process,

Benzinga · Feb 17, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Feb 17, 2022

This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart

Macy's Inc (NYSE: M) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors.

Benzinga · Feb 16, 2022

BioNTech Unveils First Modular mRNA Manufacturing Facility In Africa

BioNTech SE (NASDAQ: BNTX), which developed the first widely approved COVID-19 shot together with Pfizer Inc (NYSE: PFE),

Asharq Al-Awsat · Feb 16, 2022

BioNTech Pledges African Access to its Future Cancer Drugs

Germany's BioNTech, which is preparing to produce its COVID-19 vaccine or other disease-preventing shots in Africa, said that novel cancer therapies it is working on will in future be available on the continent at affordable prices. "We pledge as BioNTech to develop our cancer medicines also according to the needs…

The Independent UK · Feb 16, 2022

BioNTech plans modular vaccine factories in Africa

German vaccine maker BioNTech unveiled plans Wednesday to establish manufacturing facilities in Africa that would boost the availability of much-needed medicines on the continent

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Feb 14, 2022

Why BioNTech Shares Are Falling Today

BioNTech SE (NASDAQ: BNTX) is trading lower Monday morning after the U.S. Food and Drug Administration (FDA) requested additional data before approving its COVID-19 vaccine for children aged six months to four years old.

The Guardian - UK · Feb 8, 2022

Pfizer accused of pandemic profiteering as profits double

Drugmaker makes $37bn in vaccine sales and predicts bumper year ahead from Covid jabs and pill

Asharq Al-Awsat · Feb 2, 2022

Pfizer Seeks US Approval of Covid Vaccine for Children under 5

Pfizer and BioNTech said Tuesday they are seeking emergency authorization from US health regulators for use of their Covid vaccine for children aged over six months and under five years. If the Food and Drug Administration (FDA) authorizes the two-shot regimen, it will become the first Covid vaccine available to…

The Guardian - AU · Feb 2, 2022

Covid news: Anger as Tory MP says lockdown breach ‘like parking fine’; Germany could relax restrictions in March – as it happened

Pfizer-BioNTech seeks US approval for under-5s Covid inoculation; Lithuania to scrap Covid pass on Saturday

Benzinga · Feb 1, 2022

Pfizer Could Seek COVID-19 Vaccine Emergency Approval For Children Under 5 This Week

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are likely to submit a request for an emergency use authorization to the U.S.

StockNews.com · Jan 26, 2022

Down Close to 40% Year-To-Date, Now is a Good Time to Scoop Up Moderna and BioNTech

The ongoing market correction has caused the shares of popular vaccine makers Moderna (MRNA) and BioNTech (BNTX) to decline nearly 40% in price so far this year. However, because the demand for COVID-19 vaccines remains strong globally, these companies are expected to generate substantial revenues and profits in the coming…

Benzinga · Jan 25, 2022

What Are Whales Doing With BioNTech

Someone with a lot of money to spend has taken a bearish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

1 … 6 7 8 9

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.